Last updated on December 2019

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Psoriasis
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject has a diagnosis of Palmoplantar Pustulosis with or without pustulotic arthro-osteitis (PAO) for at least 24 weeks before screening.
  2. Subject has a total score of PPPASI: 12 at screening and baseline.
  3. Subject has moderate or severe pustules/vesicles on palms or soles (PPPASI severity score: 2) at screening and baseline.
  4. Subject has inadequate response to treatment with topical steroid and/or topical vitamin D3 derivative preparations prior to or at screening.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has a diagnosis of plaque-type psoriasis.
  2. Subject has the presence of pustular psoriasis in any part of the body other than the palms and soles.
  3. Subject has obvious improvement during screening ( 5 PPPASI total score improvement during the screening).
  4. Subject has received any procedures for focal infection (e.g, tonsillectomy and dental therapy) within 24 weeks of baseline.
  5. Subject has periodontitis obviously requiring treatment at screening.
  6. Subject has chronic or recurrent tonsillitis or sinusitis requiring any continuous treatment for a month or more at screening.
  7. Subject has evidence of skin conditions of hands and feet that would interfere with evaluations of the effect of study medication.
  8. Subject is pregnant or breastfeeding.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.